Casey Blood
Family · Fairbanks, AKNPI 1396295374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$428
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$422
- Merck$393
- Axsome Therapeutics, Inc.$390
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,73599%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $1,306 |
| AbbVie | 51 | $1,297 |
| Novo Nordisk | 16 | $428 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $422 |
| Merck | 19 | $393 |
| Axsome Therapeutics, Inc. | 12 | $390 |
| Neurocrine Biosciences, Inc. | 17 | $379 |
| Lilly USA, LLC | 13 | $330 |
| GSK | 8 | $174 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $151 |
| Teva Pharmaceuticals USA, Inc. | 7 | $142 |
| Alkermes, Inc. | 7 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $121 |
| Lundbeck LLC | 4 | $111 |
| Pfizer | 4 | $95 |
| Clarus Therapeutics Inc. | 4 | $76 |
| Exact Sciences | 3 | $74 |
| Novartis | 3 | $70 |
| Biohaven Pharmaceuticals, Inc. | 4 | $68 |
| Amgen | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| Rhythm Pharmaceuticals, Inc. | 3 | $59 |
| Verona Pharma, Inc. | 2 | $47 |
| Tactile Systems Technology Inc | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Gilead | 1 | $21 |
| TMS Neurohealth Centers Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Medtronic | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,790 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 196 | $259,542 |
| VraylarCariprazine Hcl | 169 | $144,484 |
| FarxigaDapagliflozin Propanediol | 208 | $115,477 |
| IngrezzaValbenazine Tosylate | 11 | $88,907 |
| OzempicSemaglutide | 68 | $86,525 |
| JardianceEmpagliflozin | 170 | $84,657 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $69,832 |
| RexultiBrexpiprazole | 45 | $65,969 |
| Dupixent SyringeDupilumab | 11 | $47,680 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 62 | $46,267 |
| EliquisApixaban | 81 | $43,326 |
| VerquvoVericiguat | 25 | $34,363 |
| LinzessLinaclotide | 38 | $27,924 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $26,637 |
| BelsomraSuvorexant | 38 | $21,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $330 | $276,379362 claims |
| AbbVieVraylar, Linzess, Qulipta, Viibryd | $1,297 | $190,541245 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $1,306 | $150,758254 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $379 | $88,90711 claims |
| Novo NordiskOzempic | $428 | $86,52568 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $174 | $84,440103 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $156 | $65,96945 claims |
| MerckVerquvo, Belsomra | $393 | $55,41663 claims |
| PfizerEliquis | $95 | $43,32681 claims |
| NovartisEntresto | $70 | $10,89338 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $121 | $6,50120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 315 family providers in Alaska.
Other family in Fairbanks
- Kristy BloodFairbanks$7K
- Teal VingerFairbanks$5K
- Brianna GrahamFairbanks$4K
- Joan DigeorgeFairbanks$3K
- Robert RosentreterFairbanks$2K
- Karolina PriebeFairbanks$2K
- Ruth RosentreterFairbanks$1K
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Whitney CarlsonSoldotna$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.